Emerging diagnostic and therapeutic options for treating mucormycosis

Matthew W. McCarthy, Thomas J. Walsh

Research output: Contribution to journalReview article

Abstract

Introduction: Early diagnosis and treatment of mucormycosis remain challenges in clinical practice. Diagnosis typically involves direct tissue sampling and histopathologic examination, which may take days to confirm. Recently, nucleic acid amplification and hybridization has emerged as an adjunctive modality in the diagnosis of mucormycosis. Areas covered: Nested, semi-nested, and multiplex PCR have tremendous potential for the rapid and reliable diagnosis of invasive fungal infections, but are not routinely used in clinical practice. Here, we review technological hurdles to widespread implementation as well as novel therapeutic options for the treatment of mucormcyosis. These include combination therapy, novel drug targets that draw on structure-activity relationships, and alternative drug development pathways, which rely on pharmacodynamics modeling. Expert opinion: Mucormycosis is an uncommon yet life-threatening infection, and robust, prospective, randomized clinical trials to define optimal therapeutic strategies are an ongoing challenge for investigators. Advantageous strategies include crossover designs, multicenter collaboration, well-defined contemporaneous control populations, data sharing, and refinement of clinically relevant and biologically tenable endpoints. Support is also needed to bolster the development of novel antifungal agents to treat mucormycosis and other orphan mycoses.

Original languageEnglish (US)
Pages (from-to)1253-1261
Number of pages9
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number12
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Mucormycosis
Nucleic Acid Hybridization
Information Dissemination
Mycoses
Antifungal Agents
Multiplex Polymerase Chain Reaction
Expert Testimony
Therapeutics
Structure-Activity Relationship
Combination Drug Therapy
Cross-Over Studies
Early Diagnosis
Randomized Controlled Trials
Research Personnel
Polymerase Chain Reaction
Infection
Pharmaceutical Preparations
Population

Keywords

  • Isavuconazole
  • microarray
  • multiplex PCR
  • nested PCR
  • shotgun sequencing

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Emerging diagnostic and therapeutic options for treating mucormycosis. / McCarthy, Matthew W.; Walsh, Thomas J.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 12, 01.12.2016, p. 1253-1261.

Research output: Contribution to journalReview article

McCarthy, Matthew W. ; Walsh, Thomas J. / Emerging diagnostic and therapeutic options for treating mucormycosis. In: Expert Opinion on Orphan Drugs. 2016 ; Vol. 4, No. 12. pp. 1253-1261.
@article{55792416767e403f82c3284ca89aea11,
title = "Emerging diagnostic and therapeutic options for treating mucormycosis",
abstract = "Introduction: Early diagnosis and treatment of mucormycosis remain challenges in clinical practice. Diagnosis typically involves direct tissue sampling and histopathologic examination, which may take days to confirm. Recently, nucleic acid amplification and hybridization has emerged as an adjunctive modality in the diagnosis of mucormycosis. Areas covered: Nested, semi-nested, and multiplex PCR have tremendous potential for the rapid and reliable diagnosis of invasive fungal infections, but are not routinely used in clinical practice. Here, we review technological hurdles to widespread implementation as well as novel therapeutic options for the treatment of mucormcyosis. These include combination therapy, novel drug targets that draw on structure-activity relationships, and alternative drug development pathways, which rely on pharmacodynamics modeling. Expert opinion: Mucormycosis is an uncommon yet life-threatening infection, and robust, prospective, randomized clinical trials to define optimal therapeutic strategies are an ongoing challenge for investigators. Advantageous strategies include crossover designs, multicenter collaboration, well-defined contemporaneous control populations, data sharing, and refinement of clinically relevant and biologically tenable endpoints. Support is also needed to bolster the development of novel antifungal agents to treat mucormycosis and other orphan mycoses.",
keywords = "Isavuconazole, microarray, multiplex PCR, nested PCR, shotgun sequencing",
author = "McCarthy, {Matthew W.} and Walsh, {Thomas J.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1080/21678707.2016.1252672",
language = "English (US)",
volume = "4",
pages = "1253--1261",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Emerging diagnostic and therapeutic options for treating mucormycosis

AU - McCarthy, Matthew W.

AU - Walsh, Thomas J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction: Early diagnosis and treatment of mucormycosis remain challenges in clinical practice. Diagnosis typically involves direct tissue sampling and histopathologic examination, which may take days to confirm. Recently, nucleic acid amplification and hybridization has emerged as an adjunctive modality in the diagnosis of mucormycosis. Areas covered: Nested, semi-nested, and multiplex PCR have tremendous potential for the rapid and reliable diagnosis of invasive fungal infections, but are not routinely used in clinical practice. Here, we review technological hurdles to widespread implementation as well as novel therapeutic options for the treatment of mucormcyosis. These include combination therapy, novel drug targets that draw on structure-activity relationships, and alternative drug development pathways, which rely on pharmacodynamics modeling. Expert opinion: Mucormycosis is an uncommon yet life-threatening infection, and robust, prospective, randomized clinical trials to define optimal therapeutic strategies are an ongoing challenge for investigators. Advantageous strategies include crossover designs, multicenter collaboration, well-defined contemporaneous control populations, data sharing, and refinement of clinically relevant and biologically tenable endpoints. Support is also needed to bolster the development of novel antifungal agents to treat mucormycosis and other orphan mycoses.

AB - Introduction: Early diagnosis and treatment of mucormycosis remain challenges in clinical practice. Diagnosis typically involves direct tissue sampling and histopathologic examination, which may take days to confirm. Recently, nucleic acid amplification and hybridization has emerged as an adjunctive modality in the diagnosis of mucormycosis. Areas covered: Nested, semi-nested, and multiplex PCR have tremendous potential for the rapid and reliable diagnosis of invasive fungal infections, but are not routinely used in clinical practice. Here, we review technological hurdles to widespread implementation as well as novel therapeutic options for the treatment of mucormcyosis. These include combination therapy, novel drug targets that draw on structure-activity relationships, and alternative drug development pathways, which rely on pharmacodynamics modeling. Expert opinion: Mucormycosis is an uncommon yet life-threatening infection, and robust, prospective, randomized clinical trials to define optimal therapeutic strategies are an ongoing challenge for investigators. Advantageous strategies include crossover designs, multicenter collaboration, well-defined contemporaneous control populations, data sharing, and refinement of clinically relevant and biologically tenable endpoints. Support is also needed to bolster the development of novel antifungal agents to treat mucormycosis and other orphan mycoses.

KW - Isavuconazole

KW - microarray

KW - multiplex PCR

KW - nested PCR

KW - shotgun sequencing

UR - http://www.scopus.com/inward/record.url?scp=85000460113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000460113&partnerID=8YFLogxK

U2 - 10.1080/21678707.2016.1252672

DO - 10.1080/21678707.2016.1252672

M3 - Review article

AN - SCOPUS:85000460113

VL - 4

SP - 1253

EP - 1261

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 12

ER -